Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach.

Cancer medicine - 1 Aug 2024

Islam Sirajul, Amin Md Al, Rengasamy Kannan R R, Mohiuddin A K M, Mahmud Shahin

Abstract excerpt

BACKGROUND: Breast cancer, a leading cause of female mortality, is closely linked to mutations in estrogen receptor beta (ESR2), particularly in the ligand-binding domain, which contributed to altered signaling pathways and uncontrolled cell growth. OBJECTIVES/AIMS: This study investigates the molecular and structural aspects of ESR2 mutant proteins to identify shared pharmacophoric regions of ESR2 mutant...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Estrogen Receptor beta

Share to Hydrogen Bonding

Share to Ligands

Share to Models, Molecular

Share to Molecular Docking Simulation

Share to Molecular Dynamics Simulation

Source

Open in PubMed Open full text

Identifiers

PMID: 39101505
DOI: 10.1002/cam4.70074
PMCID: PMC11299079

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Structure-based pharmacophore modeling for precision inhibition of mutant ESR2 in breast cancer: A systematic computational approach.PMID 39101505Read ↗

Structural insights into conformational stability of ESR1 and structure base screening of new potent inhibitor for the treatment of Breast CancerSemantic proximity Read ↗

Targeting dysregulation signatures of p53-MDM2 interactions to identify newer small molecule inhibitors for cancer therapy: Insight from computational directionSemantic proximity Read ↗

Protein-Ligand Based Pharmacophore Approach against ERK5 Involved in Breast Cancer; In-Silico Study of Flavonoids from Blighia sapidaSemantic proximity Read ↗

Identification of Novel Natural Dual HDAC and Hsp90 Inhibitors for Metastatic TNBC Using e-Pharmacophore Modeling, Molecular Docking, and Molecular Dynamics StudiesSemantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

Pharmacophore-Model-Based Virtual-Screening Approaches Identified Novel Natural Molecular Candidates for Treating Human NeuroblastomaSemantic proximity Read ↗

Dual mechanism estrogen receptor inhibitorsSemantic proximity Read ↗

Screening and identification of phytochemical drug molecules against mutant BRCA1 receptor of breast cancer using computational approaches.Semantic proximity Read ↗

Targeting Unique Ligand Binding Domain Structural Features Downregulates DKK1 in Y537S ESR1 Mutant Breast Cancer CellsSemantic proximity Read ↗

Multitarget Design of Steroidal Inhibitors Against Hormone-Dependent Breast Cancer: An Integrated In Silico ApproachSemantic proximity Read ↗

[Effect of ESR1 Somatic Mutations on SERM/SERD Binding: Insights from Molecular Docking and Molecular Dynamics Simulations].Semantic proximity Read ↗

Computational and Functional Analyses of HER2 Mutations Reveal Allosteric Activation Mechanisms and Altered Pharmacologic Effects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.